Maka Javakhia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maka Javakhia has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Ketevani Gabunia
Akaki Tsereteli State University, Faculty of Medicine, Department of Pharmacy, Kutaisi, Georgia
2 shared publications - Nato Alavidze
Akaki Tsereteli State University, Faculty of Medicine, Kutaisi, Georgia
2 shared publications - Nino Abuladze
Akaki Tsereteli State University, Georgia
2 shared publications - Nodar Sulashvili
Tbilisi State Medical University, Tbilisi, Georgia
2 shared publications Ada (Adel) Tadevosyan
Yerevan State Medical University after Mkhitar Heratsi; International Academy of Sciences of Ecology and Life Safety (MANEB); Law Academy; Association of Psychiatrists of Armenia; World Association of Psychiatrists; International Association for Traumatic Stress; World Association for Biological Psychiatry; International Association “Stress and Behavior”; Tbilisi, Georgia – Yerevan, Armenia – Los Angeles, USA
1 shared publication- David Aphkhazava
The University of Georgia, Tbilisi, Georgia
1 shared publication
Latest Publications
- Open Access
- 16 September 2026
- Published by Public Health Institute of Georgia in Georgian Medical Journal
- Vol. 1 (4)
Multidisciplinary Clinical Pharmacology in Complex Pharmacotherapy: Drug-Related Errors, Pharmacovigilance, and Evidence-Based Strategies for Medication Safety—A Systematic Review and Meta-Analysis
Background: Complex pharmacotherapy has become a defining feature of modern clinical care, particularly in older adults, patients with multimorbidity, and those moving across care settings. As the number of prescribed medicines increases, so does the risk of drug-related errors, adverse drug reactions, inappropriate prescribing, and preventable medication-related harm. Clinical pharmacology offers a practical bridge between therapeutic complexity and safer prescribing, monitoring, and deprescribing. This systematic review and meta-analysis synthesizes evidence on the burden, determinants, and prevention of medication-related harm in complex pharmacotherapy. Methods: We conducted a systematic review and meta-analysis in accordance with PRISMA guidelines. Electronic databases including PubMed/MEDLINE, Embase, Scopus, Web of Science, and Cochrane Library were searched from inception to 2024. Eligible studies included observational studies reporting medication-related errors, adverse drug events, or drug-related hospital use in adults exposed to polypharmacy (≥5 concurrent medicines) or complex pharmacotherapy, alongside interventional studies evaluating medication safety strategies. Risk of bias was assessed using design-specific tools (Newcastle-Ottawa Scale, Cochrane ROB, ROBINS-I), and evidence certainty was graded using GRADE. Random-effects meta-analyses were performed where clinical and methodological homogeneity permitted. Results: From 2,847 initially identified records, 87 studies met inclusion criteria, with 42 contributing to quantitative synthesis. The pooled prevalence of preventable medication harm was 3.0% (95% CI 2.4–3.6%), with higher rates in intensive care (5.2%) and older adults (4.1%). Polypharmacy prevalence among older adults was 41.4%, with adverse drug reaction frequencies increasing from 11.5% (2–5 medications) to 16.9% (≥5 medications). Potentially inappropriate prescribing affected 34.2% of older adults and was significantly associated with adverse drug events (OR 1.26, 95% CI 1.11–1.44). Medication discrepancies occurred in 53.7% of patients during care transitions, with discharge discrepancies doubling 30-day readmission risk (RR 2.12, 95% CI 1.76–2.55). Pharmacist-led reconciliation reduced adverse drug event-related hospital revisits by 67% (RR 0.33, 95% CI 0.20–0.53). Multicomponent interventions demonstrated the largest effects (medication errors RR 0.28, 95% CI 0.18–0.44), with favorable cost-effectiveness profiles ($2,500–$5,000 per QALY gained). Conclusion: Medication safety in complex pharmacotherapy is best approached as a systems problem rather than a single-prescriber issue. Evidence supports clinically grounded, pharmacology-informed strategies centered on structured medication review, safer transitions of care, stronger pharmacovigilance, and multidisciplinary stewardship. These findings are directly relevant to health systems in Georgia and the wider region, where aging populations, multimorbidity, and fragmented care increasingly converge. Keywords: Complex Pharmacotherapy; Medication Safety; Polypharmacy; Pharmacovigilance; Drug-Related Errors; Systematic Review.
- 16 September 2026
- Published by Public Health Institute of Georgia in Georgian Medical Journal
- Vol. 1 (4)
Open AccessMultidisciplinary Clinical Pharmacology in Complex Pharmacotherapy: Drug-Related Errors, Pharmacovigilance, and Evidence-Based Strategies for Medication Safety—A Systematic Review and Meta-Analysis
Background: Complex pharmacotherapy has become a defining feature of modern clinical care, particularly in older adults, patients with multimorbidity, and those moving across care settings. As the number of prescribed medicines increases, so does the risk of drug-related errors, adverse drug reactions, inappropriate prescribing, and preventable medication-related harm. Clinical pharmacology offers a practical bridge between therapeutic complexity and safer prescribing, monitoring, and deprescribing. This systematic review and meta-analysis synthesizes evidence on the burden, determinants, and prevention of medication-related harm in complex pharmacotherapy. Methods: We conducted a systematic review and meta-analysis in accordance with PRISMA guidelines. Electronic databases including PubMed/MEDLINE, Embase, Scopus, Web of Science, and Cochrane Library were searched from inception to 2024. Eligible studies included observational studies reporting medication-related errors, adverse drug events, or drug-related hospital use in adults exposed to polypharmacy (≥5 concurrent medicines) or complex pharmacotherapy, alongside interventional studies evaluating medication safety strategies. Risk of bias was assessed using design-specific tools (Newcastle-Ottawa Scale, Cochrane ROB, ROBINS-I), and evidence certainty was graded using GRADE. Random-effects meta-analyses were performed where clinical and methodological homogeneity permitted. Results: From 2,847 initially identified records, 87 studies met inclusion criteria, with 42 contributing to quantitative synthesis. The pooled prevalence of preventable medication harm was 3.0% (95% CI 2.4–3.6%), with higher rates in intensive care (5.2%) and older adults (4.1%). Polypharmacy prevalence among older adults was 41.4%, with adverse drug reaction frequencies increasing from 11.5% (2–5 medications) to 16.9% (≥5 medications). Potentially inappropriate prescribing affected 34.2% of older adults and was significantly associated with adverse drug events (OR 1.26, 95% CI 1.11–1.44). Medication discrepancies occurred in 53.7% of patients during care transitions, with discharge discrepancies doubling 30-day readmission risk (RR 2.12, 95% CI 1.76–2.55). Pharmacist-led reconciliation reduced adverse drug event-related hospital revisits by 67% (RR 0.33, 95% CI 0.20–0.53). Multicomponent interventions demonstrated the largest effects (medication errors RR 0.28, 95% CI 0.18–0.44), with favorable cost-effectiveness profiles ($2,500–$5,000 per QALY gained). Conclusion: Medication safety in complex pharmacotherapy is best approached as a systems problem rather than a single-prescriber issue. Evidence supports clinically grounded, pharmacology-informed strategies centered on structured medication review, safer transitions of care, stronger pharmacovigilance, and multidisciplinary stewardship. These findings are directly relevant to health systems in Georgia and the wider region, where aging populations, multimorbidity, and fragmented care increasingly converge. Keywords: Complex Pharmacotherapy; Medication Safety; Polypharmacy; Pharmacovigilance; Drug-Related Errors; Systematic Review.
- Open Access
- 3 May 2026
- Published by Public Health Institute of Georgia in Georgian Medical Journal
- Vol. 1 (2) , 1-16
Pharmacist-Led Interventions in the Management of Polypharmacy: A Systematic Review of Clinical Effectiveness, Prescribing Quality and Patient Safety Outcomes
Polypharmacy represents a growing global healthcare challenge, particularly among elderly populations with multimorbidity. While multiple pharmacological therapies are often clinically justified, inappropriate prescribing increases the risk of adverse drug reactions, hospitalisation, and reduced adherence. Pharmacist-led interventions have emerged as a strategy to optimise pharmacotherapy and improve patient outcomes.
- 3 May 2026
- Published by Public Health Institute of Georgia in Georgian Medical Journal
- Vol. 1 (2) , 1-16
Open AccessPharmacist-Led Interventions in the Management of Polypharmacy: A Systematic Review of Clinical Effectiveness, Prescribing Quality and Patient Safety Outcomes
Polypharmacy represents a growing global healthcare challenge, particularly among elderly populations with multimorbidity. While multiple pharmacological therapies are often clinically justified, inappropriate prescribing increases the risk of adverse drug reactions, hospitalisation, and reduced adherence. Pharmacist-led interventions have emerged as a strategy to optimise pharmacotherapy and improve patient outcomes.